Among FTD phenotypes, Galectin-3 was the only significantly altered biomarker in bvFTD compared to PPA, and it was significantly higher in MAPT-FTD than in other genotypes, potentially reflecting interactions between microglia and tau pathology. This evidence concerns the gene LGALS3 and frontotemporal dementia.